Advertisement
Table 2 Values, notes, and sources for variables used to predict HCV infection reduction savings
| Variable | Value | Note | Source |
|---|---|---|---|
| Proportion of PWID HCV− (I) | 25% | Average of values reported (10–40%) | Falade-Nwulia et al. [89] |
| Number of needles in circulation (N) | 1,600,000 | Increased by 33% due to additional syringe sources | Hunt and Parker [81]; German et al. [4] |
| Rate of needle sharing (s) | 2.8% | Percent of injections with a shared needle | Park et al. [83] |
| Percentage of needles not bleached (d) | 100% | Bluthenthal et al. [84] | |
| Proportion of PWID HCV+ (q) | 75% | Average of values reported (60–90%) | Falade-Nwulia et al. [89] |
| Probability of HCV infections from a single injection (t) | 3% | Kwon et al. [86]; Kaplan and O’Keefe [85] | |
| Number of sharing partners (m) | 1.2 | Per injection: ratio of receptive to distributive sharing | Park et al. [83] |
| SIF client reduction in needle-sharing (n) | 70% | From Insite | Kerr et al. [40] |
| Number of SIF clients (N) | 2100 | Approximate monthly unique Insite injection room clients | Maynard [33] |
| Total PWID population (T) | 20,950 | Adjusted by authors from Baltimore MSA to City using race census data | Tempalski et al. [87] |
| Lifetime HCV treatment cost | $68,219 | Adjusted for inflation | Razavi et al. [90] |
